secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001193125-25-069706
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA reports FY2024 R&D $13.3M, cash through late Q4 2025; Phase 3 trial to start Q2
--------------------------------------------------------------------------------

- Full-year 2024 R&D expense $13.3M (up from $9.4M); G&A $4.3M (vs $4.1M prior year).
- Raised $36M in 2024; cash expected to fund operations through late Q4 2025.
- Phase 3 IFx-2.0 trial for MCC under SPA with FDA; enrollment targeted Q2 2025 (partial clinical hold on CMC).
- Acquisition of Kineta's VISTA antibody KVA12123 targeted to close Q2 2025.
- 2025 milestones include Phase 2 VISTA trial in AML; novel bi-specific ADC platform advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525069706/0001193125-25-069706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525069706/d888264d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-069706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer